Profession Notes

With an increasing focus on bioterrorism preparedness (E. Russo, "Bioterrorism Preparedness," The Scientist, 15[1]:1, Jan. 8, 2001), researchers at the University of Pennsylvania Medical School are investigating new therapies to protect against a bioterrorist smallpox outbreak. Stuart N. Isaacs, assistant professor of medicine in the Penn Division of Infectious Diseases and John D. Lambert, professor in the Department of Pathology & Laboratory Medicine have received $1.1 million from the Nat

Written byKate Devine
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

With an increasing focus on bioterrorism preparedness (E. Russo, "Bioterrorism Preparedness," The Scientist, 15[1]:1, Jan. 8, 2001), researchers at the University of Pennsylvania Medical School are investigating new therapies to protect against a bioterrorist smallpox outbreak. Stuart N. Isaacs, assistant professor of medicine in the Penn Division of Infectious Diseases and John D. Lambert, professor in the Department of Pathology & Laboratory Medicine have received $1.1 million from the National Institutes of Health for a four-year study. According to Isaacs the ultimate goal of the project is to develop new immunotherapeutic agents for people experiencing complications from smallpox vaccination and possibly for treating smallpox virus infection itself. In the past, complications were treated with a preparation of vaccinia immune globulin obtained by blood donors. "However, this preparation is in very short supply and cannot be easily produced," he notes. Routine vaccination of populations stopped when the World Health Organization declared ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies